StageZero Life Sciences Ltd.
SZLS
株式のランク
#36085
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
株価
$0.02770208
最終同期: 2025-03-10
時価総額
$2.92M
変化（1日）
-0.46%
変化（1年）
443.18%
国
CA
取引 StageZero Life Sciences Ltd. (SZLS)
カテゴリー
Healthcare
の時価総額 StageZero Life Sciences Ltd.(SZLS)
時価総額: $2.92M
October 2026時点で、StageZero Life Sciences Ltd. の時価総額は $2.92M です。これは、当社のデータによると、StageZero Life Sciences Ltd. が世界で36085th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
StageZero Life Sciences Ltd. の時価総額の履歴（2009 から 2026 まで）
SZLS最も人気のあるトップ5と比較stocks
